

## GENITOURINARY DISEASE SITE COMMITTEE

CHELSEA HOTEL, TORONTO, ON

ROOM: CHURCHILL BALLROOM A

SATURDAY APRIL 26TH, 2025: 8:30 AM – 12:30 PM

CHAIR : SEBASTIEN HOTTE

CO-CHAIRS : TAMIM NIAZI AND WASSIM KASSOUF

SENIOR INVESTIGATORS: MARIAM JAFRI AND WENDY PARULEKAR

### CME Credits:

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

### Learning Objectives:

- Identify and address, through clinical trial and translational research, the disease burden associated with genitourinary malignancies in Canada.
- Identify clinical trial research opportunities within the Canadian Cancer Trials Group.
- Integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct.
- Apply best practices in clinical trials conduct and analysis to the Canadian Cancer Trials Genitourinary Disease Site Committee Research agenda.
- To provide a learning and mentoring environment supportive to new investigators.

8:30 am	Welcome	Sebastien Hotte
8:35 am	Ongoing Trials	
	<b>PR.24: ASCENDE-SBRT:</b> Androgen Suppression Combined with Elective Nodal and a Dose Escalated Boost. A Non-Inferiority, Phase 3 Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost	Andrew Loblaw
	<b>PR.25:</b> Option-DDR: A Randomized Phase III Trial Investigating Platinum and Taxane Chemotherapy in Metastatic Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage	Michael Kolinsky
	<b>PR.26:</b> Triple Switch: Randomised phase III trial for patients with Metastatic Castration Sensitive Prostate Cancer who have a PSA>0.2 after 6 months after ADT and ARPI treatment – patients randomized to continuing ADT and ARPI or ADT+ ARPI + docetaxel	Michael Ong
	<b>SC31/TEMPO:</b> Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)	Harriet Richardson
9:20am	Coffee Break	



9:30am	<b>New Concepts</b>	
	DIRECT Trial	Rachel Glickman
	PACE trial ICR phase 3 RCT of post-operative moderately hypofractionated RT vs. SBRT in prostate cancer	Eric Tseng
	Stereotactic Ablative Radiotherapy for Locally Recurrent Prostate Cancer with Rectal Hydrogel Spacer	Amandeep Taggar
	Post Adjuvant Pembrolizumab Trial	Jeffrey Graham
	De-escalation trial using CtDNA	Bernie Eigl
10:45am	<b>Coffee Break</b>	
10:55am	Practicum/ developments in Bladder Cancer	Guliz Ozgun
11:05am	Emerging clinical ctDNA technology and GU cancers	Alex Wyatt
11:25am	Guest Lecture: Current Trials in Bladder Cancer including BLC.6 and future Bladder Trials	Matt Galsky
12:20pm	<b>Ongoing Trials: Accrual Status</b>	Mariam Jafri
	<b>BLC.6: MODERN:</b> An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer	
	<b>PR19:</b> A Randomized Phase II Trial Evaluating High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer	
	<b>PR.24:</b> Androgen Suppression Combined with Elective Nodal Irradiation and Dose Escalated Prostate Treatment: A Non-Inferiority, Phase III Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost in Patients with Unfavourable Risk Localized Prostate Cancer (ASCENDE-SBRT)	
	<b>PR.25:</b> Option-DDR: A Randomized Phase III Trial Investigating Platinum and Taxane Chemotherapy in Metastatic Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage	
	<b>PR.26:</b> Triple Switch: Randomised phase III trial for patients with Metastatic Castration Sensitive Prostate Cancer who have a PSA>0.2 after 6 months after ADT and ARPI treatment – patients randomized to continuing ADT and ARPI or ADT+ ARPI + docetaxel	
12:30pm	<b>Closing Remarks</b>	Sebastien Hotte/ Mariam Jafri



### **Ongoing Trials: Closed to Accrual**

**BLC.1/SWOG S1011:** Phase III Surgical Trial to Evaluate the Benefit of Standard versus an Extended Pelvic Lymphadenectomy Performed at the Time Of Radical Cystectomy For Muscle Invasive Urothelial Cancer

**BLC4/SWOG S1605:** Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer

**PR17/ ANZUP 1304:** Randomised Phase III Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic

**REC4/ECOG-ACRIN EA8143:** A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

**PR.21 PLUDO (Prostate Lutetium/Docetaxel):** A Randomized Phase II Study of <sup>177</sup>Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease

**PR.22:** Darolutamide Augments Standard Therapy for Localized High-Risk Cancer of the Prostate (DASL-HiCaP)

